Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study

BACKGROUND: Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised. We sought to analyse the antitumour activity and tox...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Chanzá, Nieves Martínez, Xie, Wanling, Bilen, Mehmet Asim, Dzimitrowicz, Hannah, Burkart, Jarred, Geynisman, Daniel M, Balakrishnan, Archana, Bowman, I Alex, Jain, Rohit, Stadler, Walter, Zakharia, Yousef, Narayan, Vivek, Beuselinck, Benoit, McKay, Rana R, Tripathi, Abhishek, Pachynski, Russell, Hahn, Andrew W, Hsu, JoAnn, Shah, Sumit A, Lam, Elaine T, Rose, Tracy L, Mega, Anthony E, Vogelzang, Nicholas, Harrison, Michael R, Mortazavi, Amir, Plimack, Elizabeth R, Vaishampayan, Ulka, Hammers, Hans, George, Saby, Haas, Naomi, Agarwal, Neeraj, Pal, Sumanta K, Srinivas, Sandy, Carneiro, Benedito A, Heng, Daniel Y C, Bosse, Dominick, Choueiri, Toni K, Harshman, Lauren C
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849381/
https://ncbi.nlm.nih.gov/pubmed/30827746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30907-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars